EUVIMEDEUVIMED entdecken
Open Access

Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020

Catherine G Derington iD, Adam P Bress iD, Jennifer S Herrick iD, Joshua A Jacobs iD, Alexander R Zheutlin iD, Ransmond O Berchie iD, Molly B Conroy iD, William C Cushman iD, Jordan B King iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Catherine G Derington und 8 weiteren Autor:innen. Beteiligte Einrichtung: Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fixed‐dose combination (FDC) antihypertensive products improve blood pressure control and adherence among patients with hypertension. It is unknown to what degree commercially available FDC products meet the current hypertension management prescription patterns in the United States. Methods and Results This cross‐sectional analysis of the National Health and Nutrition Examination Surveys 2015 to March 2020 included participants with hypertension taking ≥2 antihypertensive medications (N=2451). After constructing each participant's regimen according to antihypertensive classes used, we estimated the extent to which the 7 class‐level FDC regimens available in the United States as of January 2023 would match the regimens used. Among a weighted population of 34.1 million US adults (mean age, 66.0 years; 52.8% women; 69.1% non‐Hispanic White race and ethnicity), the proportions using 2, 3, 4, and ≥5 antihypertensive classes were 60.6%, 28.2%, 9.1%, and 1.6%, respectively. The 7 FDC regimens were among 189 total regimens used (3.7%). Overall, 52.7% (95% confidence interval [CI], 48.5%‐57.0%, 18.0 million US adults) of the population were taking a regimen that was available as a class equivalent FDC product, and 47.3% (95% CI, 43.0‐51.5%, 16.1 million US adults) were using a regimen not available as a class‐equivalent FDC product.

Conclusions

About half of US adults with hypertension taking ≥2 antihypertensive classes are using a regimen that is not commercially available as a class‐equivalent FDC product as of January 2023. To maximize the potential benefit of FDCs to improve medication adherence (and thus blood pressure control) among patients taking multiple antihypertensive medications, use of FDC‐compatible regimens and improvements in the product landscape are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsHypertensionHumansAdultFemaleUnited StatesAgedMaleNutrition SurveysCross-Sectional StudiesBlood PressureMedication Adherence

Stichwörter der Autor:innen

antihypertensiveblood pressurefixed‐dose combinationhypertensionpolypillsingle‐pill combination

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA.
  • Department of Internal Medicine, Spencer Fox Eccles School of Medicine University of Utah Salt Lake City UT USA.
  • Department of Preventive Medicine University of Tennessee Health Science Center TN Memphis USA.
  • Institute for Health Research, Kaiser Permanente Colorado Aurora CO USA.

ORCID-Profile: Catherine G Derington, Adam P Bress, Jennifer S Herrick, Joshua A Jacobs, Alexander R Zheutlin, Ransmond O Berchie, Molly B Conroy, William C Cushman, Jordan B King

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS
  • NCRR NIH HHS

Zitieren

APA

Derington, C. G., Bress, A. P., Herrick, J. S., Jacobs, J. A., Zheutlin, A. R., Berchie, R. O., Conroy, M. B., Cushman, W. C., & King, J. B. (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028573

Vancouver

Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, et al. Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028573

BibTeX
@article{Derington2023,
  author = {Derington, Catherine G and Bress, Adam P and Herrick, Jennifer S and Jacobs, Joshua A and Zheutlin, Alexander R and Berchie, Ransmond O and Conroy, Molly B and Cushman, William C and King, Jordan B},
  title = {Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed‐Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028573}
}
Kostenlos starten →